Results 1 to 10 of about 1,960 (193)
Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy [PDF]
Global & Regional Health Technology Assessment, 2021 Purpose: The objective of this analysis was to compare the cost per responder between risankizumab and secukinumab among patients with moderate-to-severe plaque psoriasis in Italy.
Paolo Gisondi +3 more
doaj +2 more sources
Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real‐life experience and therapeutic response to other biological drugs [PDF]
Dermatologic Therapy, Volume 35, Issue 12, December 2022., 2022 Abstract Adalimumab is the only biological drug approved to date for the treatment of moderate and/or severe hidradenitis suppurativa. Adverse events reported during therapy include paradoxical psoriasiform reactions. No guidelines are currently available for the management of this clinical condition.
Lorenza Burzi +5 more
wiley +2 more sources
Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis) [PDF]
Journal of the European Academy of Dermatology and Venereology, Volume 37, Issue 1, Page 93-103, January 2023., 2023 Abstract Background Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin‐23. It is approved for treatment of moderate–severe chronic plaque psoriasis. Objectives We conducted a 52‐week retrospective study to assess the effectiveness and safety of tildrakizumab in a real‐life setting.
Alessandra Narcisi +19 more
wiley +2 more sources
Artificial intelligence processing electronic health records to identify commonalities and comorbidities cluster at Immuno Center Humanitas [PDF]
Clinical and Translational Allergy, Volume 12, Issue 6, June 2022., 2022 Abstract Background Comorbidities are common in chronic inflammatory conditions, requiring multidisciplinary treatment approach. Understanding the link between a single disease and its comorbidities is important for appropriate treatment and management.
Pierandrea Morandini +10 more
wiley +2 more sources
Nature Reviews Disease Primers, 2016 Psoriasis is a chronic, immune-mediated disorder with cutaneous and systemic manifestations and substantial negative effects on patient quality of life. Psoriasis has a strong, albeit polygenic, genetic basis. Whereas approximately half of the accountable genetic effect of psoriasis maps to the major histocompatibility complex, >70 other loci have been
Greb, Jacqueline E. +8 more
+10 more sources
Research progress on continuity of care for psoriasi
Huli yanjiu, 2018 张曼莉, 李平, 李菲, 叶苓
doaj +1 more source
Cold Spring Harbor Perspectives in Medicine, 2014 Psoriasis is a common chronic inflammatory skin disease with a spectrum of clinical phenotypes and results from the interplay of genetic, environmental, and immunological factors. Four decades of clinical and basic research on psoriasis have elucidated many of the pathogenic mechanisms underlying disease and paved the way to effective targeted ...
Paola, Di Meglio +2 more
openaire +2 more sources
Cutis, 2021 A Elbow and forearm with erythematous, well-demarcated, pink plaques with mild micaceous scale in a 42-year-old White woman. B Elbow and forearm with violaceous, well-demarcated plaques with micaceous scale and hyperpigmented patches around the active plaques in a 58-year-old Black man.
Candrice R, Heath, Richard P, Usatine
openaire +6 more sources
Canadian Medical Association Journal, 2012 Psoriasis is a common relapsing and remitting immune-mediated inflammatory disease that affects the skin and joints. This review focuses on current immunogenetic concepts, key cellular players, and axes of cytokines that are thought to contribute to disease pathogenesis.
Anatoli, Freiman, Benjamin, Barankin
openaire +4 more sources